Literature DB >> 17507604

Vasopressin-induced nitric oxide production in rat inner medullary collecting duct is dependent on V2 receptor activation of the phosphoinositide pathway.

Paul M O'Connor1, Allen W Cowley.   

Abstract

We previously reported that arginine vasopressin (AVP) stimulates the production of nitric oxide (NO) in inner medullary collecting duct (IMCD) via activation of V2 receptors (V2R) and the mobilization of intracellular Ca(2+). The aim of this study was to determine the pathway(s) through which this response is mediated. IMCDs were dissected from male Sprague-Dawley rats and intracellular Ca(2+) concentration ([Ca(2+)](i)) and NO production were measured using a fluorescence imaging system. AVP (100 nmol/l) produced a rapid increase [Ca(2+)](i) of 381 +/- 78 nmol/l that was followed by a significant increase of NO production (166 +/- 61%). The specific nonpeptide V2R antagonist OPC31260 (1 microM), but not the V1R antagonist OPC21268 (1 microM), inhibited the increase in [Ca(2+)](i) (up to 91 +/- 5%) and abolished the NO response to AVP. Both the phospholipase C inhibitor U73112 (3 microM) and the inositol (1,4,5) tri-phosphate 3 receptor blocker 2-APB (75 microM) reduced the peak [Ca(2+)](i) response to AVP (by 65 +/- 9 and 59 +/- 15%, respectively) and abolished the NO response. Although forskolin (100 microM; an activator of adenylyl cyclase) elicited a moderate increase in [Ca(2+)](i), neither preincubation with the adenylyl cyclase inhibitor 2'-5'-dideoxyadenosine (50 microM) nor the protein kinase A (PKA) inhibitor PKA(14-22) (100 microM) significantly inhibited peak [Ca(2+)](i) in response to AVP. IMCD [Ca(2+)](i) responses to AVP were reduced by 72 +/- 8% when incubated in Ca(2+)-free media and could be completely abolished by preincubation with the Ca(2+)-ATPase inhibitor thapsigargin. We conclude that AVP-induced NO production in IMCD is dependent on V2R activation of the phosphoinositide pathway and the mobilization of Ca(2+) from both intracellular and extracellular pools.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17507604     DOI: 10.1152/ajprenal.00052.2007

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  10 in total

Review 1.  Modulation of pressure-natriuresis by renal medullary reactive oxygen species and nitric oxide.

Authors:  Paul M O'Connor; Allen W Cowley
Journal:  Curr Hypertens Rep       Date:  2010-04       Impact factor: 5.369

Review 2.  Renal medullary oxidative stress, pressure-natriuresis, and hypertension.

Authors:  Allen W Cowley
Journal:  Hypertension       Date:  2008-10-13       Impact factor: 10.190

3.  Enhanced amiloride-sensitive superoxide production in renal medullary thick ascending limb of Dahl salt-sensitive rats.

Authors:  Paul M O'Connor; Limin Lu; Carlos Schreck; Allen W Cowley
Journal:  Am J Physiol Renal Physiol       Date:  2008-06-25

4.  Vasopressin in chronic kidney disease: an elephant in the room?

Authors:  Vicente E Torres
Journal:  Kidney Int       Date:  2009-11       Impact factor: 10.612

5.  Phosphoproteomic profiling reveals vasopressin-regulated phosphorylation sites in collecting duct.

Authors:  Amar D Bansal; Jason D Hoffert; Trairak Pisitkun; Shelly Hwang; Chung-Lin Chou; Emily S Boja; Guanghui Wang; Mark A Knepper
Journal:  J Am Soc Nephrol       Date:  2010-01-14       Impact factor: 10.121

6.  Sex differences in ET-1 receptor expression and Ca2+ signaling in the IMCD.

Authors:  Chunhua Jin; Joshua S Speed; Kelly A Hyndman; Paul M O'Connor; David M Pollock
Journal:  Am J Physiol Renal Physiol       Date:  2013-08-14

Review 7.  Bench-to-bedside review: Vasopressin in the management of septic shock.

Authors:  James A Russell
Journal:  Crit Care       Date:  2011-08-11       Impact factor: 9.097

8.  Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients.

Authors:  James A Russell; Jean-Louis Vincent; Anne Louise Kjølbye; Håkan Olsson; Allan Blemings; Herbert Spapen; Peder Carl; Pierre-Francois Laterre; Lars Grundemar
Journal:  Crit Care       Date:  2017-08-15       Impact factor: 9.097

Review 9.  Role of vasopressin in current anesthetic practice.

Authors:  Keun Suk Park; Kyung Yeon Yoo
Journal:  Korean J Anesthesiol       Date:  2017-05-26

10.  Induction of RAGE shedding by activation of G protein-coupled receptors.

Authors:  Verena V Metz; Elzbieta Kojro; Dorothea Rat; Rolf Postina
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.